Antimicrobial &Immunization for Bacterial Gastritis

Information

  • Research Project
  • 6880542
  • ApplicationId
    6880542
  • Core Project Number
    R43AI060028
  • Full Project Number
    1R43AI060028-01A1
  • Serial Number
    60028
  • FOA Number
  • Sub Project Id
  • Project Start Date
    5/15/2005 - 20 years ago
  • Project End Date
    4/30/2006 - 19 years ago
  • Program Officer Name
    VAN DE VERG, LILLIAN L.
  • Budget Start Date
    5/15/2005 - 20 years ago
  • Budget End Date
    4/30/2006 - 19 years ago
  • Fiscal Year
    2005
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    5/2/2005 - 20 years ago

Antimicrobial &Immunization for Bacterial Gastritis

[unreadable] DESCRIPTION (provided by applicant): Helicobacter pylori (Hp), a gastric bacterial pathogen of humans; infection is the cause of type B gastritis and is also strongly associated with gastric carcinoma (intestinal type) and gastric MALT lymphoma. Combination antimicrobial therapy (triple therapy with a bismuth salt, metranidazole and a broad spectrum antibiotic) is successful in 80% of Hp-infected symptomatic patients; treatment failures are expressed as recrudescence of infection and clinical signs and are associated with development of antibiotic-resistant microbes and poor patient compliance. In a previous SBIR, we have demonstrated that parenteral immunization with an Hp proteolytic digest prevents colonization in Hp-challenged gnotobiotic swine. Preliminary data suggest that activated T cells and their products, in particular, interferon gamma (IFNg), are central for this immunoprotective effect. An ideal approach to the problem of recrudescence treatment failure is to combine antimicrobial therapy with parenteral immunization in the post-treatment interval when Hp colonization levels are low to nonexistent yet the risk of eventual recurrence is real. In this SBIR proposal, we will test the hypothesis that parenteral immunizations of piglets, temporarily cleared or eradicated of infection with selected antimicrobials, will resist re-challenge inoculation with Hp. In addition, we will test the hypotheses that the mechanism of protection is, in part, mediated by IFNg and that orally administered IFNg will prevent recrudescence and may even replace current antimicrobial regimens if a positive therapeutic effect in actively infected piglets can be achieved. From these data, the feasibility of a combined antimicrobial and immunization approach for the successful treatment of symptomatic Hp disease in humans will be discerned. If these data are positive, a phase II SBIR application will be prepared to capitalize on these findings for the commercial development of this novel approach to Hp-associated gastric infection. [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    104372
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:104372\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    AMARILLO BIOSCIENCES, INC.
  • Organization Department
  • Organization DUNS
    148170533
  • Organization City
    AMARILLO
  • Organization State
    TX
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    791104225
  • Organization District
    UNITED STATES